Harper J W, Vallee B L
Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, Boston, Massachusetts 02115.
Biochemistry. 1989 Feb 21;28(4):1875-84. doi: 10.1021/bi00430a067.
Human angiogenin is a blood vessel inducing protein whose primary structure displays 33% identity to that of bovine pancreatic ribonuclease A (RNase A). Angiogenin catalyzes limited cleavage of 18S and 28S ribosomal RNA and is several orders of magnitude less potent than RNase A toward conventional substrates. A striking structural difference between angiogenin and RNase is the virtual absence of sequence similarity within the region of RNase that contains the Cys-65--Cys-72 disulfide bond. Indeed, angiogenin lacks this disulfide linkage. The present report describes the use of regional mutagenesis to generate a covalent angiogenin/RNase hybrid protein, ARH-I, where residues 58-70 of angiogenin have been replaced by the corresponding segment of RNase A (residues 59-73). The protein expressed in Escherichia coli readily folds at pH 8.5 to form the four expected disulfide bonds. The in vivo angiogenic potency of ARH-I is markedly diminished compared with that of angiogenin when examined using the chick chorioallantoic membrane assay. In contrast, its enzymatic activity is dramatically increased. With high molecular weight wheat germ RNA and tRNA, ARH-I is 660- and 300-fold more active than angiogenin, respectively, while with poly(uridylic acid), poly(cytidylic acid), cytidylyl(3'----5')adenosine (CpA), and uridylyl(3'----5')adenosine (UpA) activity is enhanced by about 200-fold. In addition, the specificity of ARH-I toward dinucleoside 3',5'-phosphates is qualitatively similar to RNase A; while angiogenin prefers cytidylyl(3'----5')guanosine (CpG) to UpA, both RNase and the hybrid prefer UpA to CpG. ARH-I also displays greater than 10-fold enhanced activity toward rRNA in intact ribosomes, while abolishing the capacity of the ribosome to support cell-free protein synthesis. The enhanced enzymatic properties of ARH-I parallel a 2-fold increase in chemical reactivity of active-site lysine and histidine residues based on rates of chemical modification. The data indicate that introduction of a region of RNase A containing the Cys-65--Cys-72 disulfide bond into angiogenin dramatically increases RNase-like enzymatic activity while reducing its angiogenicity.
人血管生成素是一种血管诱导蛋白,其一级结构与牛胰腺核糖核酸酶A(RNase A)有33%的同源性。血管生成素催化18S和28S核糖体RNA的有限切割,且对传统底物的活性比RNase A低几个数量级。血管生成素与RNase之间一个显著的结构差异是,在RNase中包含Cys-65--Cys-72二硫键的区域几乎没有序列相似性。实际上,血管生成素缺乏这种二硫键连接。本报告描述了利用区域诱变产生一种共价血管生成素/RNase杂合蛋白ARH-I,其中血管生成素的58-70位残基已被RNase A的相应片段(59-73位残基)取代。在大肠杆菌中表达的该蛋白在pH 8.5时容易折叠形成四个预期的二硫键。当使用鸡胚绒毛尿囊膜试验检测时,ARH-I的体内血管生成能力与血管生成素相比明显降低。相反,其酶活性显著增加。对于高分子量小麦胚芽RNA和tRNA,ARH-I的活性分别比血管生成素高660倍和300倍,而对于聚(尿苷酸)、聚(胞苷酸)、胞苷酰(3'----5')腺苷(CpA)和尿苷酰(3'----5')腺苷(UpA),活性增强约200倍。此外,ARH-I对3',5'-磷酸二核苷的特异性在性质上与RNase A相似;血管生成素相对于UpA更喜欢胞苷酰(3'----5')鸟苷(CpG),而RNase和杂合蛋白都更喜欢UpA而不是CpG。ARH-I对完整核糖体中的rRNA也表现出超过10倍的活性增强,同时消除了核糖体支持无细胞蛋白质合成的能力。基于化学修饰速率,ARH-I增强的酶学性质与活性位点赖氨酸和组氨酸残基化学反应性增加2倍平行。数据表明,将含有Cys-65--Cys-72二硫键的RNase A区域引入血管生成素中,可显著增加RNase样酶活性同时降低其血管生成性。